# Cerevance

**Canonical:** https://apis.io/providers/cerevance/  
**Website:** https://www.cerevance.com  
**APIs profiled:** 0

Cerevance is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. Its proprietary NETSseq platform profiles gene expression across specific human brain cell types from post-mortem tissue to identify previously undiscovered, cell-type-specific drug targets, powering a pipeline of small-molecule candidates for Parkinson's disease, Alzheimer's disease, epilepsy, and other neurodegenerative and psychiatric conditions. Surfaced as a portfolio company of GV; profiled in the API Evangelist network. Cerevance publishes no public API, developer portal, or SDK.

## Kin Score — 10.5 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 10.5).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Cerevance Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Life Sciences, Biotechnology, Pharmaceuticals, Drug Discovery, Central Nervous System, Neuroscience

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/cerevance/). Scores are computed from the provider's own public artifacts under a published rubric.